EUCTR2020-001669-35-ES进行中（未招募）1 期
Interventional, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of eptinezumab for the preventive treatment of migraine in patients with a dual diagnosis of migraine and Medication Overuse Headache.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 182
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. The patient has a diagnosis of migraine as defined by IHS ICHD-3 guidelines confirmed at the Screening Visit with a history of migraine onset of at least 12 months prior to the Screening Visit.
- •2. The patient has =8 migraine days per month for each month on average within the past 3 months prior to the Screening Visit.
- •3. The patient has a diagnosis of MOH as defined by IHS ICHD-3 guidelines.
- •4. The patient has headache on =15 days/month for each month within the past 3 months prior to the Screening Visit.
- •5. The patient has regular overuse of one or more drugs that can be taken for acute and/or symptomatic treatment of headache, for >3 months.
- •6. The patient has =15 to =26 headache days, of which =8 days were assessed as migraine days during the Screening Period, based on prospectively collected information in the eDiary.
- •7. The patient overuses drugs that can be taken for acute and/or symptomatic treatment of headache during the Screening Period, based on prospectively collected information in the eDiary.
- •8. The patient has demonstrated compliance with the Headache eDiary by entry of data for at least 24 of the 28 days of the Screening Period.
- •9. The patient has had an onset of migraine at <50 years of age.
- •10. The patient is aged =18 and =75 years at the Screening Visit.
- •Other inclusion criteria may apply.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 145
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 37
排除标准
- •1. The patient has experienced failure on a previous treatment targeting the calcitonin gene-related peptide (CGRP) pathway.
- •2. The patient has confounding and clinically significant pain syndromes, (for example, fibromyalgia, chronic low back pain, complex regional pain syndrome).
- •3. The patient has a diagnosis of acute or active temporomandibular disorder.
- •4. The patient has a history or diagnosis of chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes such as hemiplegic migraine (sporadic and familial), ophthalmoplegic migraine, migraine with brainstem aura and migraine with
- •neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or long
- •5. Patients with a lifetime history of psychosis, bipolar mania, or dementia are excluded. Patients with other psychiatric conditions whose symptoms are not controlled or who have not been adequately treated for a minimum of 6 months prior to screening are also excluded.
- •6. The patient has a history of clinically significant cardiovascular disease, including uncontrolled hypertension, vascular ischaemia or thromboembolic events (for example, cerebrovascular accident, deep vein thrombosis, or pulmonary embolism).
- •Other exclusion criteria may apply
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Patients That Are Not Helped by Previous Preventive TreatmentsMigraine in patients with unsuccessful prior preventive treatmentsMedDRA version: 20.0Level: PTClassification code 10027599Term: MigraineSystem Organ Class: 10029205 - Nervous system disordersEUCTR2019-004497-25-FIH. Lundbeck A/S840
进行中（未招募）
1 期
A study to evaluate the efficacy and safety of eptinezumab in patients with episodic cluster headacheEpisodic cluster headacheMedDRA version: 24.0Level: PTClassification code 10059133Term: Cluster headacheSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-001969-37-DKH. Lundbeck A/S304
进行中（未招募）
1 期
A Study of Eptinezumab in Participants With Migraine and Medication Overuse HeadacheMigraine and medication overuse headacheMedDRA version: 20.0Level: PTClassification code 10027599Term: MigraineSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10072720Term: Medication overuse headacheSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-003049-40-NOH. Lundbeck A/S570
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Patients That Are Not Helped by Previous Preventive TreatmentsMigraine in patients with unsuccessful prior preventive treatmentsMedDRA version: 20.0Level: PTClassification code 10027599Term: MigraineSystem Organ Class: 10029205 - Nervous system disordersEUCTR2019-004497-25-SEH. Lundbeck A/S840
进行中（未招募）
1 期
Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophreniaschizophrenia with persistent prominent negative symptomsMedDRA version: 20.0Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2018-001581-42-LVH. Lunbeck A/S240